SCV-07: Additional Phase IIa data
A gene expression analysis of RNA samples from 59 head and neck cancer patients receiving chemotherapy in a double-blind, dose-ranging, U.S. Phase IIa trial showed that patients receiving 0.1 mg/kg SCV-07 had significantly higher levels of macrophage migration inhibitory factor (MIF) (p<0.049), macrophage inflammatory protein-1 beta ( CCL4; MIP1B) (p<0.049), and vascular endothelial growth factor (VEGF) (p<0.015) compared to placebo at the end of the 7-week treatment period. SCV-07-treated patients also had significantly lower levels of IL-1 alpha vs. placebo (p<0.045). SciClone said patients receiving 0.02 mg/kg SCV-07 did not demonstrate the same immune response as the high-dose group. Additionally, the company said it identified 2 undisclosed gene clusters associated with immune system modification that were predictive of patient response to SCV-07. Data were presented at the AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver. ...